<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03397914</url>
  </required_header>
  <id_info>
    <org_study_id>103</org_study_id>
    <nct_id>NCT03397914</nct_id>
  </id_info>
  <brief_title>Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections</brief_title>
  <official_title>Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized study comparing different colistin dosing regimens in paediatric
      cancer patient with MDR gram-negative infection or sepsis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to:

        1. Evaluate the clinical outcome of two different dosing regimen of IV colistin in the
           treatment of children with multidrug resistant gram-negative infections or sepsis.

        2. To estimate the frequency of colistin associated adverse effects.

        3. To correlate the serum colistin concentration and MIC to microbiological clearance and
           clinical outcome
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical improvement,</measure>
    <time_frame>7- 14 days</time_frame>
    <description>time to defervescence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>incidence of colistin related nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microbiological clearance</measure>
    <time_frame>7-14 days</time_frame>
    <description>time to clearance of cultures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gram-Negative Bacterial Infections</condition>
  <condition>Pediatric Cancer</condition>
  <condition>Colistin</condition>
  <condition>Colistin Adverse Reaction</condition>
  <condition>MIC</condition>
  <arm_group>
    <arm_group_label>Group A Regimen:</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>- Loading dose 2.5 mg/kg followed by maintenance dose 1.25mg/Kg every 12 hours in accordance with manufacturer insert</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B Regimen:</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>- Loading dose 5 mg/kg followed by maintenance dose 2.5 mg/Kg every 12 hours in accordance with manufacturer insert</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistin</intervention_name>
    <description>study the effect of different dose of colistin 5mg/kg vs 2.5 mg/kg in MDR gram negative infections</description>
    <arm_group_label>Group A Regimen:</arm_group_label>
    <arm_group_label>Group B Regimen:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between one year and 18 years

          2. All paediatric cancer patients who are prescribed intravenous colistin due to:

               -  Sepsis due to MDR or minimally susceptible gram-negative bacteria

               -  History of MDR gram-negative infection or sepsis due to organisms sensitive to
                  colistin.

               -  Culture result consistent with MDR gram negative for this febrile neutropenic
                  episode.

               -  Patient in sepsis and colistin was administered empirically to increase
                  antibiotic coverage.

        Exclusion Criteria:

          1. Age less than one year or over 18 years

          2. Patients with renal impairment

          3. Colistin use less than 72 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yosr Samia Abou Sedira</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yosr Samia Abou Sedira, bcs.</last_name>
    <phone>201227531255</phone>
    <email>yosrsamia@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yosr Samia Abou Sedira</last_name>
    <phone>201227531255</phone>
    <email>yosrsamia@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Institute Egypt</name>
      <address>
        <city>Cairo</city>
        <state>Cairo Governorate</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yosr Samia Abou Sedira</last_name>
      <phone>201227531255</phone>
      <email>yosrsamia@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem. 1977;46:723-63. Review.</citation>
    <PMID>197881</PMID>
  </reference>
  <reference>
    <citation>Komura S, Kurahashi K. Partial purification and properties of L-2,4-diaminobutyric acid activating enzyme from a polymyxin E producing organism. J Biochem. 1979 Oct;86(4):1013-21.</citation>
    <PMID>500578</PMID>
  </reference>
  <reference>
    <citation>Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Aust. 1970 Nov 14;2(20):923-4.</citation>
    <PMID>5486295</PMID>
  </reference>
  <reference>
    <citation>Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005 May 1;40(9):1333-41. Epub 2005 Mar 22. Review. Erratum in: Clin Infect Dis. 2006 Jun 15;42(12):1819. Dosage error in article text.</citation>
    <PMID>15825037</PMID>
  </reference>
  <reference>
    <citation>Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012 Jun;54(12):1720-6. doi: 10.1093/cid/cis286. Epub 2012 Mar 15.</citation>
    <PMID>22423120</PMID>
  </reference>
  <reference>
    <citation>Hernández Orozco H, Lucas Resendiz E, Castañeda JL, De Colsa A, Ramirez Mayans J, Johnson KM, Gonzalez N, Caniza MA. Surveillance of healthcare associated infections in pediatric cancer patients between 2004 and 2009 in a public pediatric hospital in Mexico city, Mexico. J Pediatr Hematol Oncol. 2014 Mar;36(2):96-8. doi: 10.1097/MPH.0b013e31827e7f4c.</citation>
    <PMID>23337552</PMID>
  </reference>
  <reference>
    <citation>Gupta A, Kapil A, Lodha R, Kabra SK, Sood S, Dhawan B, Das BK, Sreenivas V. Burden of healthcare-associated infections in a paediatric intensive care unit of a developing country: a single centre experience using active surveillance. J Hosp Infect. 2011 Aug;78(4):323-6. doi: 10.1016/j.jhin.2011.04.015. Epub 2011 Jun 14.</citation>
    <PMID>21676495</PMID>
  </reference>
  <reference>
    <citation>Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol. 2011 Oct;11(5):464-9. doi: 10.1016/j.coph.2011.07.004. Epub 2011 Aug 9. Review.</citation>
    <PMID>21835694</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

